Stutt\u00adgart \u2014 Gleiss Lutz has advi\u00adsed Chinese Suns\u00adhine Lake Pharma Co., Ltd. on the German law aspects of its IPO on the Hong Kong Stock Exch\u00adange and the priva\u00adtiza\u00adtion of its subsi\u00addiary YiChang HEC.<\/p>\n
In connec\u00adtion with the IPO of Suns\u00adhine Lake Pharma, Gleiss
\nLutz has prepared a legal opinion on its prin\u00adci\u00adpal German subsi\u00addiary, HEC Pharm GmbH.<\/p>\n
The priva\u00adtiza\u00adtion was effec\u00adted through a merger of YiChang HEC with Suns\u00adhine Lake Pharma by way of acqui\u00adsi\u00adtion, wher\u00adeby new H shares of Suns\u00adhine Lake Pharma were offe\u00adred as compen\u00adsa\u00adtion for the acqui\u00adsi\u00adtion of the H shares of the rele\u00advant share\u00adhol\u00adders of YiChang HEC. The priva\u00adtiza\u00adtion and the IPO were condi\u00adtio\u00adnal upon each other. Upon comple\u00adtion, YiChang HEC was delis\u00adted and Suns\u00adhine Lake Pharma was listed on the Hong Kong Stock Exch\u00adange, with the share\u00adhol\u00adders of YiChang HEC beco\u00adming share\u00adhol\u00adders of Suns\u00adhine Lake Pharma through a share swap as part of the privatization. <\/p>\n
Suns\u00adhine Lake Pharma is a verti\u00adcally inte\u00adgra\u00adted phar\u00admaceu\u00adti\u00adcal company enga\u00adged in the rese\u00adarch and deve\u00adlo\u00adp\u00adment, manu\u00adfac\u00adtu\u00adring and commer\u00adcia\u00adliza\u00adtion of phar\u00admaceu\u00adti\u00adcal products, with a focus on inno\u00adva\u00adtive medi\u00adci\u00adnes. The company is also active in the areas of modi\u00adfied new drugs, gene\u00adrics and biosimilars. <\/p>\n
Advi\u00adsor to Suns\u00adhine Lake Pharma: Gleiss Lutz<\/strong><\/p>\n Led by Dr. Michael Burian<\/strong> (Part\u00adner, Frank\u00adfurt) and Dr. Yixiao Li<\/strong> (both M&A, Stuttgart). www.gleisslutz.com<\/span> <\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":" Stutt\u00adgart \u2014 Gleiss Lutz has advi\u00adsed Chinese Suns\u00adhine Lake Pharma Co., Ltd. on the German law aspects of its IPO on the Hong Kong Stock Exch\u00adange and the priva\u00adtiza\u00adtion of its subsi\u00addiary YiChang HEC. In connec\u00adtion with the IPO of Suns\u00adhine Lake Pharma, Gleiss Lutz has prepared a legal opinion on its prin\u00adci\u00adpal German subsidiary, [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-56713","post","type-post","status-publish","format-standard","hentry","category-news-en"],"yoast_head":"\n
\nDr. Anselm Chris\u00adti\u00adan\u00adsen (Part\u00adner, Stutt\u00adgart), Sonja Hilgert (Berlin),
\nAlex\u00adan\u00addra Br\u00fccher (all M&A, Stutt\u00adgart), Dr. Stephan Aubel (Part\u00adner,
\nCapi\u00adtal Markets Law, Frank\u00adfurt), Dr. Enno Burk (Part\u00adner), Christoph
\nSchoppe, Dr. Xiao Chen (all Health\u00adcare & Life Scien\u00adces, all Berlin),
\nDr. Jacob von Andreae (Part\u00adner), Aylin Hoffs (Coun\u00adsel, both
\nForeign Trade Law, both D\u00fcssel\u00addorf), Dr. Ocka Stumm (Part\u00adner), Dr.
\nJohan\u00adnes Heck (both Tax Law, both Frank\u00adfurt), Jose\u00adfine Chakrabarti
\n(Coun\u00adsel, Employ\u00adment Law, Berlin), Maxi\u00admi\u00adlian Leisenheimer
\n(Real Estate Law, Frank\u00adfurt), Dr. Simon Wagner (Coun\u00adsel, Commercial,
\nStutt\u00adgart), Simon Clemens Wegman (Data Protec\u00adtion Law, Berlin).<\/p>\n